Quest for the right Drug
אטרקוריום קלצקס 10 מ"ג/מ"ל ATRACURIUM KALCEKS 10 MG/ML (ATRACURIUM BESYLATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
תמיסה להזרקהאינפוזיה : SOLUTION FOR INJECTION / INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Interactions : אינטראקציות
4.5 Interaction with other medicinal products and other forms of interaction The neuromuscular block produced by Atracurium Kalceks may be increased by the concomitant use of inhalational anaesthetics such as halothane, isoflurane and enflurane. In common with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with: - antibiotics, including the aminoglycosides, polymyxins, spectinomycin, tetracyclines, lincomycin and clindamycin - anti-arrhythmic drugs: propranolol, calcium channel blockers, lidocaine, procainamide and quinidine - diuretics: furosemide and possibly mannitol, thiazide diuretics and acetazolamide - magnesium sulfate - ketamine - lithium salts - ganglion blocking agents, trimetaphan, hexamethonium. Rarely certain drugs may aggravate or unmask latent myasthenia gravis or actually induce a myasthenic syndrome; increased sensitivity to Atracurium Kalceks would be consequent on such a development. Such drugs include various antibiotics, β-blockers (propranolol, oxprenolol), antiarrhythmic drugs (procainamide, quinidine), antirheumatic drugs (chloroquine, D-penicillamine), trimetaphan, chlorpromazine, steroids, phenytoin and lithium. The onset of non-depolarising neuromuscular block is likely to be lengthened and the duration of block shortened in patients receiving chronic anticonvulsant therapy. The administration of combinations of non-depolarising neuromuscular blocking agents in conjunction with Atracurium Kalceks may produce a degree of neuromuscular blockage in excess of that which might be expected were an equipotent total dose of Atracurium Kalceks administered. Any synergistic effect may vary between different drug combinations. A depolarising muscle relaxant such as suxamethonium chloride should not be administered to prolong the neuromuscular blocking effects of non-depolarising blocking agents such as atracurium, as this may result in a prolonged and complex block which can be difficult to reverse with anticholinesterase drugs. Treatment with anticholinesterases, commonly used in the treatment of Alzheimer’s disease e.g. donepezil, may shorten the duration and diminish the magnitude of neuromuscular blockade with atracurium.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה מוגבלת לשימוש בבתי חולים או אשפוז יום
מידע נוסף